臺灣博碩士論文加值系統

肺癌是全世界因癌症死亡最主要的原因，而其高死亡率的主因是由於肺癌轉移率及抗藥性極高所致。IGF-I是一個多功能的生長因子具有促進生長、抗細胞凋亡的作用。當IGF-I結合到IGF-IR，即造成IGF-IR的酪胺酸磷酸化，活化的接受器會吸引IRS及Shc並使其磷酸化。IRS蛋白包含許多酪胺酸殘基，可做為許多訊息分子的結合位，包含PI3K、Grb2、SHP-2以及Nck。適當的IGF-I訊號傳遞調控正常的生理功能，如胎兒發展、組織生長、代謝；然而IGF-I訊號失調時被描述和許多癌症相關，其中包括肺癌。因此我們想去探究IGF-I訊號傳遞在許多肺癌行為中所扮演的角色，我們使用肺腺癌細胞株CL1-0及其高侵入性亞株CL1-5。我們的結果顯示，CL1-0表現較高量的IGF-IR及IRS-2而CL1-5則表現較高量的IRS-1。在IGF-I刺激下，誘發CL1-0 中IGF-IR及IRS-2的酪胺酸磷酸化，CL1-5中IRS-1的酪胺酸磷酸化。由此可知，酪胺酸磷酸化程度之差異主要是因為這些分子的表現量不同所造成。我們想更進一步去探討在CL1-0及 CL1-5中IGF-IR、IRS-1 及IRS-2不同表現量對生長、抗藥性、失巢凋亡敏感性的影響。結果顯示，降低CL1-0細胞株IGF-IR表現量可降低細胞生長，但出乎我們預期卻是降低對doxorubicin的敏感性，對失巢凋亡的抗性則是沒有明顯的影響。降低CL1-5細胞株IRS-1表現量可降低細胞生長，同時降低對抗doxorubicin及破壞細胞黏附所誘發細胞凋亡的能力。降低CL1-0細胞株IRS-2表現量對生長、抗藥性、失巢凋亡敏感性的影響甚微。

Lung cancer is the leading cause of cancer death worldwide. The high mortality of lung cancer is due to metastasis and resistance to chemotherapy. Insulin-like growth factor (IGF-I) is a pleiotropic growth factor with potent mitogenic and anti-apoptotic functions. It initiates cascades of signaling by inducing tyrosine phosphorylation of the IGF-I receptor (IGF-IR). The active receptor then recruits and phosphorylates the IRS and Shc. IRS protein contains multiple tyrosine residues, which serves as docking sites for various signaling molecules including phosphatidylinositol 3-kinase (PI3K), Grb2, SHP-2 and Nck. Proper IGF-I signaling is involved in the normal control of fetal development, tissue growth, and metabolism; however, deregulation of IGF signaling has been described in several cancer types, including lung cancer. To investigate the role of IGF-I signaling in several behavior of lung tumor, the lung adenocarcinoma cell line CL1-0 and its highly invasive subline CL1-5 are used. Our results show that CL1-0 expresses higher levels of IGF-IR and IRS-2, whereas CL1-5 exhibits greater expression of IRS-1. In response to IGF-I stimulation, tyrosine phosphorylation of IGF-IR and IRS-2 is mainly restricted to CL1-0, but phosphorylation of IRS-1 is more pronounced in CL1-5. The extents of tyrosine phosphorylation of these signaling molecules coincide with their expression levels. We then examine whether differential expression of IGF-IR, IRS-1 and IRS-2 in CL1-0 and CL1-5 affects their capacity in proliferation, drug resistance and anoikis resistance. Out results show that knocking down IGF-IR expression in CL1-0 results in a decrease in cell growth, unexpectedly, a decrease in the sensitivity to doxorubicin. There is no obvious effect on
4
anoikis resistance in these cells. Lowering IRS-1 expression in CL1-5 inhibits cell growth and jeopardizes their ability to resist doxorubicin- and detachment-induced apoptosis. Knocking down IRS-2 levels in CL1-0 exerts negligible changes in cell growth, drug resistance and anoikis resistance.

中文摘要 1
英文摘要 3
縮寫檢所表 5
第一章、 緒論 7
第二章、 實驗材料及方法 17
第三章、 實驗結果 25
第四章、 討論 31
第五章、 圖表 36
參考文獻 48

1. Hakama M, Coleman MP, Alexe DM, Auvinen A: Cancer screening: evidence and practice in Europe 2008. Eur J Cancer 2008, 44（10）:1404-1413.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59（4）:225-249.
3. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P: The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009, 4（7）:792-801.
4. Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, Licker M, Ferguson MK, Faivre-Finn C, Huber RM et al: ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients （surgery and chemo-radiotherapy）. Eur Respir J 2009, 34（1）:17-41.
5. Albain KS, Swann RS, Rusch VW, Turrisi AT, 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374（9687）:379-386.
6. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55（2）:74-108.
7. Pleasance ED, Stephens PJ, O''Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature, 463（7278）:184-190.
8. Cross FT: Invited commentary: residential radon risks from the perspective of experimental animal studies. Am J Epidemiol 1994, 140（4）:333-339.
9. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, Chen CY, Lee H: Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007, 67（22）:10686-10693.
10. Klein F, Amin Kotb WF, Petersen I: Incidence of human papilloma virus in lung cancer. Lung Cancer 2009, 65（1）:13-18.
11. Cavalieri E, Rogan E: Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann N Y Acad Sci 2006, 1089:286-301.
12. Salmon WD, Jr., Daughaday WH: A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957, 49（6）:825-836.
13. Dulak NC, Temin HM: A partially purified polypeptide fraction from rat liver cell conditioned medium with multiplication-stimulating activity for embryo fibroblasts.
49
J Cell Physiol 1973, 81（2）:153-160.
14. Froesch ER, Buergi H, Ramseier EB, Bally P, Labhart A: Antibody-Suppressible and Nonsuppressible Insulin-Like Activities in Human Serum and Their Physiologic Significance. An Insulin Assay with Adipose Tissue of Increased Precision and Specificity. J Clin Invest 1963, 42:1816-1834.
15. Rinderknecht E, Humbel RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978, 253（8）:2769-2776.
16. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4（7）:505-518.
17. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I （Igf-1） and type 1 IGF receptor （Igf1r）. Cell 1993, 75（1）:59-72.
18. LeRoith D, Clemmons D, Nissley P, Rechler MM: NIH conference. Insulin-like growth factors in health and disease. Ann Intern Med 1992, 116（10）:854-862.
19. Lu K, Campisi J: Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB/c murine fibroblasts. Proc Natl Acad Sci U S A 1992, 89（9）:3889-3893.
20. Parrizas M, Saltiel AR, LeRoith D: Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3''-kinase and mitogen-activated protein kinase pathways. J Biol Chem 1997, 272（1）:154-161.
21. Dahn MS, Lange MP: Systemic and splanchnic metabolic response to exogenous human growth hormone. Surgery 1998, 123（5）:528-538.
22. White MF, Kahn CR: The insulin signaling system. J Biol Chem 1994, 269（1）:1-4.
23. Hartog H, Wesseling J, Boezen HM, van der Graaf WT: The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007, 43（13）:1895-1904.
24. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA et al: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5（3）:221-230.
25. Pawson T: Protein modules and signalling networks. Nature 1995, 373（6515）:573-580.
26. White MF, Maron R, Kahn CR: Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 1985, 318（6042）:183-186.
27. Patti ME, Sun XJ, Bruening JC, Araki E, Lipes MA, White MF, Kahn CR: 4PS/insulin receptor substrate （IRS）-2 is the alternative substrate of the insulin
50
receptor in IRS-1-deficient mice. J Biol Chem 1995, 270（42）:24670-24673.
28. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF: Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991, 352（6330）:73-77.
29. Miralpeix M, Sun XJ, Backer JM, Myers MG, Jr., Araki E, White MF: Insulin stimulates tyrosine phosphorylation of multiple high molecular weight substrates in Fao hepatoma cells. Biochemistry 1992, 31（37）:9031-9039.
30. Lee YH, White MF: Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004, 27（4）:361-370.
31. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG, Jr., Glasheen E, Lane WS, Pierce JH, White MF: Role of IRS-2 in insulin and cytokine signalling. Nature 1995, 377（6545）:173-177.
32. Smith-Hall J, Pons S, Patti ME, Burks DJ, Yenush L, Sun XJ, Kahn CR, White MF: The 60 kDa insulin receptor substrate functions like an IRS protein （pp60IRS3） in adipose cells. Biochemistry 1997, 36（27）:8304-8310.
33. Lavan BE, Fantin VR, Chang ET, Lane WS, Keller SR, Lienhard GE: A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem 1997, 272（34）:21403-21407.
34. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE: Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J Biol Chem 2003, 278（28）:25323-25330.
35. Sun XJ, Miralpeix M, Myers MG, Jr., Glasheen EM, Backer JM, Kahn CR, White MF: Expression and function of IRS-1 in insulin signal transmission. J Biol Chem 1992, 267（31）:22662-22672.
36. Myers MG, Jr., White MF: The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains. Diabetes 1993, 42（5）:643-650.
37. Hadsell DL, Alexeenko T, Klimentidis Y, Torres D, Lee AV: Inability of overexpressed des（1-3）human insulin-like growth factor I （IGF-I） to inhibit forced mammary gland involution is associated with decreased expression of IGF signaling molecules. Endocrinology 2001, 142（4）:1479-1488.
38. Wu X, Sallinen K, Anttila L, Makinen M, Luo C, Pollanen P, Erkkola R: Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls. Fertil Steril 2000, 74（3）:564-572.
39. Kuhne MR, Pawson T, Lienhard GE, Feng GS: The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp. J Biol Chem 1993, 268（16）:11479-11481.
40. Lee CH, Li W, Nishimura R, Zhou M, Batzer AG, Myers MG, Jr., White MF,
51
Schlessinger J, Skolnik EY: Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells. Proc Natl Acad Sci U S A 1993, 90（24）:11713-11717.
41. Amoui M, Craddock BP, Miller WT: Differential phosphorylation of IRS-1 by insulin and insulin-like growth factor I receptors in Chinese hamster ovary cells. J Endocrinol 2001, 171（1）:153-162.
42. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF: Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 1999, 23（1）:32-40.
43. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000, 21（3）:215-244.
44. Werner H, Karnieli E, Rauscher FJ, LeRoith D: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 1996, 93（16）:8318-8323.
45. Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR: AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001, 61（2）:589-593.
46. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL: Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999, 59（16）:3915-3918.
47. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B: Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 1998, 17（17）:5085-5094.
48. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002, 277（41）:38205-38211.
49. Shigematsu S, Yamauchi K, Nakajima K, Iijima S, Aizawa T, Hashizume K: IGF-1 regulates migration and angiogenesis of human endothelial cells. Endocr J 1999, 46 Suppl:S59-62.
50. Lee OH, Bae SK, Bae MH, Lee YM, Moon EJ, Cha HJ, Kwon YG, Kim KW: Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br J Cancer 2000, 82（2）:385-391.
51. Grulich-Henn J, Ritter J, Mesewinkel S, Heinrich U, Bettendorf M, Preissner KT: Transport of insulin-like growth factor-I across endothelial cell monolayers and its binding to the subendothelial matrix. Exp Clin Endocrinol Diabetes 2002, 110（2）:67-73.
52
52. Meyer GE, Shelden E, Kim B, Feldman EL: Insulin-like growth factor I stimulates motility in human neuroblastoma cells. Oncogene 2001, 20（51）:7542-7550.
53. Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M: Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ 2002, 13（2）:87-93.
54. Zhang D, Bar-Eli M, Meloche S, Brodt P: Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 2004, 279（19）:19683-19690.
55. Yoon A, Hurta RA: Insulin like growth factor-1 selectively regulates the expression of matrix metalloproteinase-2 in malignant H-ras transformed cells. Mol Cell Biochem 2001, 223（1-2）:1-6.
56. Long L, Navab R, Brodt P: Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res 1998, 58（15）:3243-3247.
57. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P: Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 2004, 202（1）:50-59.
58. Mira E, Manes S, Lacalle RA, Marquez G, Martinez AC: Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999, 140（4）:1657-1664.
59. Chen B, Liu S, Xu W, Wang X, Zhao W, Wu J: IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies. J Exp Clin Cancer Res 2009, 28:89.
60. Gualberto A, Pollak M: Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28（34）:3009-3021.
61. Mardilovich K, Pankratz SL, Shaw LM: Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009, 7:14.
62. Oft M, Akhurst RJ, Balmain A: Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002, 4（7）:487-494.
63. Karamouzis MV, Papavassiliou AG: The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med 2006, 12（12）:595-602.
64. Gibson SL, Ma Z, Shaw LM: Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 2007, 6（6）:631-637.
65. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD: Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index.
53
Cancer Res, 70（4）:1564-1572.
66. Pennisi PA, Barr V, Nunez NP, Stannard B, Le Roith D: Reduced expression of insulin-like growth factor I receptors in MCF-7 breast cancer cells leads to a more metastatic phenotype. Cancer Res 2002, 62（22）:6529-6537.
67. Pavelic J, Krizanac S, Kapitanovic S, Pavelic L, Samarzija M, Pavicic F, Spaventi S, Jakopovic M, Herceg-Ivanovi Z, Pavelic K: The consequences of insulin-like growth factors/receptors dysfunction in lung cancer. Am J Respir Cell Mol Biol 2005, 32（1）:65-71.
68. Giaccone G: Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005, 23（14）:3235-3242.
69. Berge G, Mollerup S, S OV, Hewer A, Phillips DH, Eilertsen E, Haugen A: Role of estrogen receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung. Lung Cancer 2004, 45（3）:289-297.